CoChat
Sign Up
Cited by 89Diabetes, Cardiovascular Risks, and LipoproteinsMenopause: Health Impacts and TreatmentsDiet, Metabolism, and Disease

Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study

Giordano, Domenico, Corrado, Francesco, Santamaria, Angelo, Quattrone, Simona, Pintaudi, Basilio, Di Benedetto, Antonino, D'Anna, Rosario·2011·Menopause
DOI 10.1097/gme.0b013e3181e8e1b1
Open this paper in CoChat — free account

Abstract

OBJECTIVE: The aim of this study was to evaluate whether myo-inositol, an insulin-sensitizing substance, may improve some features of metabolic syndrome in postmenopausal women. METHODS: Eighty postmenopausal women affected by the metabolic syndrome were enrolled prospectively in the study and treated with diet plus supplementation of myo-inositol (2 g BID plus diet: intervention group) or with diet plus placebo (control group) for 6 months. They were evaluated at baseline and after 6 months for insulin resistance (homeostasis model assessment ratio [HOMA] insulin resistance), lipid profile, and blood pressure. RESULTS: Myo-inositol plus diet improved systolic and diastolic blood pressure, HOMA index, cholesterol, and triglyceride serum levels with highly significant differences, compared with the groups treated only with diet and placebo. In the group treated with myo-inositol, a decrease in diastolic blood pressure (-11%), HOMA index (-75%), and serum triglycerides (-20%) and an improvement in high-density lipoprotein cholesterol (22%) were shown. CONCLUSIONS: Supplementation with myo-inositol may be considered a reliable option in the treatment of metabolic syndrome in postmenopausal women.

Integrity signals

Registry

Crossref · 10.1097/gme.0b013e3181e8e1b1

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Metabolic outcomes were assessed by all the reviews with important results: reduced insulin levels, reduced glucose levels and HOMA-IR, and improved blood pressure, triglycerides, and high-density lipoprotein.

    “Metabolic outcomes were assessed by all the reviews with important results: reduced insulin levels [47, 72, 85], reduced glucose levels and HOMA-IR, and improved blood pressure, triglycerides, and high-density lipoprotein [86].”

    From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [72]

  • In postmenopausal women affected by metabolic syndrome, myo-inositol administration in addition to diet significantly reduced diastolic blood pressure (−11%), HOMA index (−75%), and serum triglycerides (−20%), and increased high-density lipoprotein cholesterol (+22%) compared with patients only on diet.

    “Myo-inositol decreased diastolic blood pressure (−11%), HOMA index (−75%), and serum triglycerides (−20%); furthermore, the treatment increased high-density lipoprotein cholesterol (+22%).”

    From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [72]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Giordano, D., Corrado, F., Santamaria, A., Quattrone, S., Pintaudi, B., Di Benedetto, A., & D'Anna, R.
Affiliations
  • University of Reggio Calabria (IT)
  • University of Messina (IT)
ORCID
Venue
Menopause
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2011-01
Volume
18
Issue
1
Pages
102-104
ISSN
1072-3714 (ISSN-L)
DOI
10.1097/gme.0b013e3181e8e1b1
OpenAlex
W1967030744
Cited by
89
References
13
Citations by year
2025: 5 · 2024: 8 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 9 · 2019: 2 · 2018: 8 · 2017: 5 · 2016: 10 · 2015: 7 · 2014: 5 · 2013: 8 · 2012: 2
FWCI
2.90
Type
journal article
Language
en
Open access
closed
Locations
  • Menopause The Journal of The North American Menopause Society (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Keywords
myo-inositol, metabolic syndrome, postmenopausal women, insulin resistance, dietary supplementation, blood pressure, lipid profile, triglycerides, HDL cholesterol, HOMA-IR
MeSH terms
Blood Glucose, Blood Pressure, Female, Humans, Inositol, Insulin, Insulin Resistance, Lipids, Middle Aged, Prospective Studies, Body Mass Index, Postmenopause, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review